1. Sieper J. New treatment targets for axial spondyloarthritis. Rheumatology (Oxford). 2016; 55(suppl 2):ii38–ii42.
2. Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. 1999; 26:971–4.
3. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis. 2011; 70:1375–81.
4. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21:2286–91.
5. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21:2281–5.
6. Jones SD, Steiner A, Garrett SL, Calin A. The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol. 1996; 35:66–71.
7. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994; 21:1694–8.
8. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-en-dorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68:1811–8.
9. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012; 44:805–16.
10. Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med. 2014; 52:1107–17.
11. Esen B, Atay AE, Gunoz N, Gokmen ES, Sari H, Cakir I, et al. The relation of mean platelet volume with microalbuminuria and glomerular filtration rate in obese individuals without other metabolic risk factors: the role of platelets on renal functions. Clin Nephrol. 2015; 83:322–9.
12. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 2012; 59:1580–2.
13. Ju HY, Kim JK, Hur SM, Woo SA, Park KA, Park MY, et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease? Platelets. 2015; 26:143–7.
14. Karabacak M, Dogan A, Turkdogan AK, Kapci M, Duman A, Akpinar O. Mean platelet volume is increased in patients with hypertensive crises. Platelets. 2014; 25:423–6.
15. Varol E, Ozaydin M. Mean platelet volume measurement in patients with hypercholesterolemia: a methodological issue. Angiology. 2013; 64:626.
16. Wang X, Xu XL, Li XM, Zhao R, Yang X, Cong HL. Diagnostic value of mean platelet volume combined with troponin i for acute coronary syndrome. Am J Med Sci. 2016; 352:159–65.
17. Tecer D, Sezgin M, Kanık A, İncel NA, Çimen ÖB, Biçer A, et al. Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? Biomark Med. 2016; 10:967–74.
18. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75:291–4.
19. Şahin A, Yetişgin A, Şahin M, Durmaz Y, Cengiz AK. Can mean platelet volume be a surrogate marker of inflammation in rheumatic diseases? West Indian Med J. 2015; 65:165–9.
20. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets. 2010; 21:126–31.
21. Sezgin M, Tecer D, Kanık A, Kekik FS, Yeşildal E, Akaslan E, et al. Serum RDW and MPV in ankylosing spondylitis: Can they show the disease activity? Clin Hemorheol Microcirc. 2017; 65:1–10.
22. Resorlu H, Resorlu M, Gokmen F, Akbal A, Adam G, Komurcu E, et al. Association between mean platelet volume and bone mineral density in patients with ankylosing spondylitis and diagnostic value of diffusion-weighted magnetic resonance imaging. J Phys Ther Sci. 2015; 27:1137–40.
23. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27:361–8.
24. Cho SY, Jeon YL, Kim W, Kim WS, Lee HJ, Lee WI, et al. Mean platelet volume and mean platelet volume/platelet count ratio in infective endocarditis. Platelets. 2014; 25:559–61.
25. Bessman JD, Williams LJ, Gilmer PR Jr. Platelet size in health and hematologic disease. Am J Clin Pathol. 1982; 78:150–3.
26. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115:3339–47.
27. Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther. 2012; 14:R232.
28. De Luca G, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P. Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. Blood Coagul Fibrinolysis. 2012; 23:756–9.